Atea Pharmaceuticals, Inc. Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Boston MA United States (2014)

Organization Overview

First Clinical Trial
2017
NCT03219957
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Atea Pharmaceuticals | Atea Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

at-527 (14 trials)

Drugs in Phase 2 Trials (2)

at-777 (1 trial)

daclatasvir (daklinza) (1 trial)

Drugs in Phase 1 Trials (5)

at-752 (1 trial)

carbamazepine (tegretol) (1 trial)

cyclosporine (sandimmune) (1 trial)

digoxin (lanoxin) (1 trial)

rosuvastatin (crestor) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 2)

Hepatitis C (Phase 2)

Hepatitis C, Chronic (Phase 2)

Infections (Phase 2)

Virus Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 15
  • # of Trial APIs: 8